The economic case for universal pharmacare

The main argument that is typically made against the establishment of universal Pharmacare is economic in nature. However, a new CCPA report shows that the economic argument in favour of such a program is loud and clear, regardless of which industrial policy is subsequently considered. Canadians could save between 10% and 42%—up to $10.7 billion—of total drug expenditures.

Click here to read the full report.